Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123).
Witte D, Pretzell I, Reissig TM, Stein A, Velthaus JL, Alig A, Bohnenberger H, Knödler M, Kurreck A, Sulzer S, Beyer G, Dorman K, Fröhlich T, Hegenberg S, Lugnier C, Saborowski A, Vogel A, Lange S, Reichert M, Flade F, Klaas L, Utpatel K, Becker H, Bleckmann A, Wethmar K, Reinacher-Schick A, Westphalen CB. Witte D, et al. Among authors: westphalen cb. J Cancer Res Clin Oncol. 2024 Oct 1;150(10):438. doi: 10.1007/s00432-024-05954-5. J Cancer Res Clin Oncol. 2024. PMID: 39352477 Free PMC article.
Targeted RT study: results on early toxicity of targeted therapies and radiotherapy.
Konnerth D, Gaasch A, Westphalen CB, Heinrich K, Niyazi M, Eze C, Rogowski P, Marschner S, Zinn A, Belka C, Corradini S, Schönecker S. Konnerth D, et al. Among authors: westphalen cb. Radiat Oncol. 2024 Aug 29;19(1):113. doi: 10.1186/s13014-024-02494-7. Radiat Oncol. 2024. PMID: 39210363 Free PMC article.
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development.
Westphalen CB, Martins-Branco D, Beal JR, Cardone C, Coleman N, Schram AM, Halabi S, Michiels S, Yap C, André F, Bibeau F, Curigliano G, Garralda E, Kummar S, Kurzrock R, Limaye S, Loges S, Marabelle A, Marchió C, Mateo J, Rodon J, Spanic T, Pentheroudakis G, Subbiah V. Westphalen CB, et al. Ann Oncol. 2024 Nov;35(11):936-953. doi: 10.1016/j.annonc.2024.07.730. Epub 2024 Aug 25. Ann Oncol. 2024. PMID: 39187421 Free article.
ESMO Recommendations on clinical reporting of genomic test results for solid cancers.
van de Haar J, Roepman P, Andre F, Balmaña J, Castro E, Chakravarty D, Curigliano G, Czarnecka AM, Dienstmann R, Horak P, Italiano A, Marchiò C, Monkhorst K, Pritchard CC, Reardon B, Russnes HEG, Sirohi B, Sosinsky A, Spanic T, Turnbull C, Van Allen E, Westphalen CB, Tamborero D, Mateo J. van de Haar J, et al. Among authors: westphalen cb. Ann Oncol. 2024 Nov;35(11):954-967. doi: 10.1016/j.annonc.2024.06.018. Epub 2024 Jul 9. Ann Oncol. 2024. PMID: 39112111 Free article.
Correction: Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentation.
Mansour N, Heinrich K, Zhang D, Winkelmann M, Ingenerf M, Gold L, Klambauer K, Rudelius M, Klauschen F, Bergwelt-Baildon MV, Ricke J, Heinemann V, Westphalen CB, Kunz WG. Mansour N, et al. Among authors: westphalen cb. Cancer Imaging. 2024 Jul 1;24(1):82. doi: 10.1186/s40644-024-00724-5. Cancer Imaging. 2024. PMID: 38951928 Free PMC article. No abstract available.
Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentation.
Mansour N, Heinrich K, Zhang D, Winkelmann M, Ingenerf M, Gold L, Klambauer K, Rudelius M, Klauschen F, von Bergwelt-Baildon M, Ricke J, Heinemann V, Westphalen CB, Kunz WG. Mansour N, et al. Among authors: westphalen cb. Cancer Imaging. 2024 Jun 7;24(1):70. doi: 10.1186/s40644-024-00708-5. Cancer Imaging. 2024. PMID: 38849902 Free PMC article.
145 results